Aclaris Therapeutics, Inc. (ACRS) Is At $20.02 Formed Wedge; 7 Analysts Covering Tetra Tech, Inc. (TTEK)

February 6, 2018 - By Jerrie Dane

Among 13 analysts covering TETRA Tech (NASDAQ:TTEK), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. TETRA Tech had 32 analyst reports since November 9, 2015 according to SRatingsIntel. The stock has “Hold” rating by Robert W. Baird on Friday, October 6. The stock of Tetra Tech, Inc. (NASDAQ:TTEK) earned “Hold” rating by Oppenheimer on Thursday, August 3. Canaccord Genuity maintained Tetra Tech, Inc. (NASDAQ:TTEK) on Wednesday, August 9 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Wednesday, January 25. Stifel Nicolaus maintained the stock with “Hold” rating in Friday, October 13 report. On Friday, November 10 the stock rating was maintained by Robert W. Baird with “Neutral”. Canaccord Genuity upgraded the shares of TTEK in report on Tuesday, May 31 to “Buy” rating. The firm earned “Buy” rating on Wednesday, August 2 by Roth Capital. On Tuesday, April 19 the stock rating was initiated by Sidoti with “Buy”. Wunderlich maintained Tetra Tech, Inc. (NASDAQ:TTEK) rating on Monday, November 9. Wunderlich has “Buy” rating and $12.0 target. See Tetra Tech, Inc. (NASDAQ:TTEK) latest ratings:

02/02/2018 Broker: Roth Capital Rating: Buy New Target: $59.0 Maintain
10/11/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $47 New Target: $52 Maintain
19/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $52.0 Maintain
13/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $47.0 Maintain
06/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $47.0 Maintain
05/10/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
07/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $52.0 Maintain
07/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $47.0 Maintain
05/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $47.0 Maintain
09/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $52.0000 Maintain

Aclaris Therapeutics, Inc. (ACRS) formed wedge down with $18.62 target or 7.00% below today’s $20.02 share price. Aclaris Therapeutics, Inc. (ACRS) has $617.31M valuation. The stock decreased 4.48% or $0.94 during the last trading session, reaching $20.02. About 539,705 shares traded or 40.65% up from the average. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since February 6, 2017 and is uptrending. It has outperformed by 8.87% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. As per Monday, November 2, the company rating was initiated by Citigroup. The firm has “Buy” rating by Jefferies given on Thursday, August 31. As per Monday, November 2, the company rating was initiated by Jefferies. The rating was maintained by Jefferies on Friday, July 28 with “Buy”. On Friday, June 10 the stock rating was initiated by Guggenheim with “Buy”. The stock has “Buy” rating by Jefferies on Friday, August 12. As per Friday, September 30, the company rating was initiated by JMP Securities. The stock has “Buy” rating by Jefferies on Monday, September 19. The company was initiated on Monday, November 2 by William Blair. Leerink Swann initiated Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rating on Tuesday, November 29. Leerink Swann has “Outperform” rating and $54 target.

Analysts await Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings on March, 21. They expect $-0.90 EPS, down 83.67% or $0.41 from last year’s $-0.49 per share. After $-0.63 actual EPS reported by Aclaris Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.

Since October 24, 2017, it had 0 insider purchases, and 4 insider sales for $4.30 million activity. $533,310 worth of stock was sold by BATRACK DAN L on Wednesday, December 13. 696 shares were sold by CHU RONALD J, worth $34,800 on Friday, October 27.

The stock decreased 5.73% or $2.9 during the last trading session, reaching $47.75. About 371,224 shares traded or 42.64% up from the average. Tetra Tech, Inc. (NASDAQ:TTEK) has risen 54.98% since February 6, 2017 and is uptrending. It has outperformed by 38.28% the S&P500.

Tetra Tech, Inc. provides consulting and engineering services worldwide. The company has market cap of $2.67 billion. It operates through two divisions, Water, Environment and Infrastructure ; and Resource Management and Energy (RME). It has a 20 P/E ratio. The WEI segment offers early data collection and monitoring, data analysis and information technology, science and engineering applied research, engineering design, construction management, and activities and maintenance services; and climate change and energy management consulting, as well as greenhouse gas inventory assessment, certification, reduction, and management services.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.14, from 1.14 in 2017Q2. It worsened, as 23 investors sold Tetra Tech, Inc. shares while 85 reduced holdings. 23 funds opened positions while 85 raised stakes. 46.41 million shares or 2.62% less from 47.66 million shares in 2017Q2 were reported. Vanguard Gp reported 5.27 million shares. Envestnet Asset Management, a Illinois-based fund reported 13,192 shares. Advisory Research, Illinois-based fund reported 12,807 shares. Aqr Mngmt Ltd Com holds 29,119 shares. State Of Alaska Department Of Revenue has 11,335 shares. Amalgamated Savings Bank accumulated 0.01% or 7,828 shares. Minnesota-based Ameriprise has invested 0.01% in Tetra Tech, Inc. (NASDAQ:TTEK). Louisiana State Employees Retirement accumulated 22,900 shares. New York-based Sg Americas Ltd Liability Co has invested 0.01% in Tetra Tech, Inc. (NASDAQ:TTEK). Alliancebernstein Limited Partnership invested in 847,941 shares or 0.03% of the stock. Asset Mgmt One holds 135,718 shares. Ubs Asset Management Americas reported 73,500 shares stake. Principal Financial Grp Inc Inc owns 636,867 shares or 0.03% of their US portfolio. Raymond James has invested 0% in Tetra Tech, Inc. (NASDAQ:TTEK). 35,719 were accumulated by Rothschild Asset Management Inc.